Advances in the treatment of cytomegalovirus.

ABSTRACT:

Background

Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.

Sources of data

Sources of data are recently published research papers and reviews about HCMV treatments.

Areas of agreement

Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.

Areas of controversy

Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?

Growing points

Growing points are developing drugs against latently infected cells. In addition to small molecule inhibit

SUBMITTER: Krishna BA 

PROVIDER: S-EPMC6821982 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature